Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Gossamer Bio (GOSS) to $12 from $9 and keeps an Outperform rating on the shares following quarterly results. Approaching the February 2026 PROSERA topline readout, the firm continues to see success given PROSERA’s baseline population and positive Phase 2 TORREY data increasing the likelihood of achieving statistically significant 6MWD. Additionally, the first clinical site from Phase 3 SERANATA/PH-ILD has been activated, with results expected in 2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS: